University of Massachusetts v. Roslin Institute

437 F. Supp. 2d 57, 79 U.S.P.Q. 2d (BNA) 1527, 65 Fed. R. Serv. 3d 726, 2006 U.S. Dist. LEXIS 40466
CourtDistrict Court, District of Columbia
DecidedJune 20, 2006
DocketCivil Action Nos. 05-353, 05-706. Document Nos. 16, 17
StatusPublished
Cited by15 cases

This text of 437 F. Supp. 2d 57 (University of Massachusetts v. Roslin Institute) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
University of Massachusetts v. Roslin Institute, 437 F. Supp. 2d 57, 79 U.S.P.Q. 2d (BNA) 1527, 65 Fed. R. Serv. 3d 726, 2006 U.S. Dist. LEXIS 40466 (D.D.C. 2006).

Opinion

MEMORANDUM OPINION

URBINA, District Judge.

Denying the Defendants’ Motion for a Protective Order

I. INTRODUCTION

These cases come before the court under 35 U.S.C. § 146, and involve a district court review of two decisions by the Board of Patent Appeals. The plaintiffs contend that the defendants are interfering with the plaintiffs’ patents for animal cloning (Civ. Action No. 05-353) and methods of producing embryonic stem cells by nuclear transfer (Civ. Action No. 05-706). The animal cloning patent involves the method by which defendant Geron Corporation cloned the sheep “Dolly.”

The plaintiffs initiated patent dispute proceedings (known as “interference” proceedings), before the U.S. Patent and Trademark Office’s Board of Patent Appeals and Interferences (hereinafter, “the Board”), against the defendants’ patent applications. On December 20, 2004 and February 11, 2005, the Board found for the defendants as to both patent interferences.

In the current action, the plaintiffs seek reversal of the Board of Patent Appeals’s decisions. Presently before the court is the defendants’ motion for a protective order. Basically, the defendants would like to limit the scope of this action to a review of the Board of Patent Appeals’s decision. For this reason, they seek a protective order limiting the scope of discovery to issues previously discovered and raised during the Board proceedings. Because the defendants fail to demonstrate that the discovery sought is not reasonably calculated to lead to the discovery of admissible evidence or that they would suffer clearly defined and serious injury absent the issuance of a protective order, the court denies their motion for entry of a protective order.

II. BACKGROUND

A. Patent Dispute Giving Rise to Civil Action 05-353

Civil Action 05-353 (hereinafter, the “353 Action”), involves competing patents regarding methods of cloning non-human animals. On January 10, 1997, Steven Stice, working for plaintiff University of Massachusetts, submitted a patent application to clone non-human animals using “nuclear transfer” with “a cycling (non-quiescent) donor cell.” 353 Action Compl. ¶ 9. This application resulted in U.S. Patent No. 5,945,577 (hereinafter the “577 Patent”). Id.; Defs.’ Mot. ¶ 2. From this patent, plaintiff Advanced Cell Technologies, Inc., as an assignee of the 577 Patent, cloned two heifers, affectionately named George and Charlie, from cells of an adult cow. 353 Action Compl. at 2.

Meanwhile, on August 29, 2000, Keith Campbell, working for defendant Roslin Institute, submitted a patent application, U.S. Patent Application No. 09/650,194 (hereinafter the “194 Application”) to clone non-human animals, 353 Action Compl. ¶ 9; Defs.’ Mot. ¶ 3, using “nuclear transfer” with “a quiescent donor cell,” 353 Action Compl. at 2. From this patent, defendants Geron Corporation and Exeter Life Sciences, as assignees of the 194 Application, cloned a lamb, infamously known as “Dolly,” from an adult ewe. Id. at 1-2.

B. Patent Dispute Giving Rise to Civil Action 05-706

Civil Action 05-706 (hereinafter, the “706 Action”), involves competing patents regarding methods of producing embryonic stem cells by nuclear transfer. 706 *60 Action Compl. at 1-2. On March 22, 2001, the U.S. Patent and Trademark Office issued U.S. Patent No. 6,235,970 (hereinafter, the “970 Patent”) to Steven Stice. Id. ¶ 9. On November 21, 2001, Keith Campbell filed his own patent application for a similar technology, U.S. Patent Application No. 09/989,126 (hereinafter, the “126 Application”).

C. Procedural History

Disputing who owned the patent for the non-human animal cloning technology and the nuclear transfer technology, the parties initiated interference proceedings. Essentially, the purpose of the interference proceedings is to ascertain which patent holder is actually entitled to hold that patent and, conversely, which party is interfering with the legitimate patent holder’s patent. The court will refer to the U.S. Patent Office’s Interference proceedings regarding the non-human animal cloning technologies as the “746 Interference” and to the U.S. Patent Office’s Interference proceedings regarding the nuclear transfer technology as the “192 Interference.”

On December 20, 2004, the Board found in favor of Campbell’s patent as to its patented method for cloning non-human animals, 353 Action Compl. ¶ 12, and on February 11, 2005, the Board found in favor of Campbell’s patent as to its nuclear transfer technology. Having secured unfavorable rulings by the Board as to both the 746 Interference and the 192 Interference actions, the plaintiffs initiated the 353 Action and the 706 Action respectively. See 353 Action Compl.; See 706 Action Compl. In these actions, the plaintiffs argue that the court should set aside the Board’s decisions because they are, for various reasons, erroneous.

The parties are currently enmeshed in a discovery dispute. As part of the plaintiffs’ preparation for their case, they seek depositions of Ian Wilmut, a named inventor, and David Wells, a witness who submitted a declaration in the Interference actions. Pis.’ Opp’n at 1. The defendants have moved for a protective order to prevent these depositions from going forward. The court now turns to that motion.

III. ANALYSIS

A. Legal Standard for the Issuance of a Protective Order

Protective orders are issued for good cause shown and to prevent annoyance, embarrassment, oppression, undue burden, or expense. Fed. R. Civ. P. 26(c). A motion for a protective order usually follows the movant’s unsuccessful attempt and both parties’ good faith efforts to resolve the matter. Id. A protective order may, inter alia, deny discovery completely, limit the conditions, time, place, or topics of discovery, or limit the manner in which the confidential information is to be revealed. Id.; Burka v. Dep’t of Health and Human Servs., 87 F.3d 508, 518 (D.C.Cir.1996). The moving party bears the burden of showing that there is good cause for the issuance of the order. Fed. R. Civ. P. 26(c). Since such a motion limits the liberal discovery rules, “good cause” is only established when the movant demonstrates that disclosure would cause a clearly defined and serious injury. Glenmede Trust Co. v. Thompson, 56 F.3d 476, 483 (3d Cir.1995). A district court may not grant a protective order without a showing of good cause. EEOC v. Nat’l Children’s Ctr., Inc.,

Related

Nb v. District of Columbia
District of Columbia, 2024
Mannina v. District of Columbia
District of Columbia, 2020
Buie v. District of Columbia
District of Columbia, 2018
Strike 3 Holdings, LLC v. Doe
District of Columbia, 2018
Breiterman v. U.S. Capitol Police
District of Columbia, 2017
Navajo Nation v. Peabody Holding Co.
255 F.R.D. 37 (District of Columbia, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
437 F. Supp. 2d 57, 79 U.S.P.Q. 2d (BNA) 1527, 65 Fed. R. Serv. 3d 726, 2006 U.S. Dist. LEXIS 40466, Counsel Stack Legal Research, https://law.counselstack.com/opinion/university-of-massachusetts-v-roslin-institute-dcd-2006.